{"id":746023,"date":"2019-06-03T15:15:00","date_gmt":"2019-06-03T15:15:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-phase-3-solo3-trial-demonstrated-a-72-objective-response-rate-in-patients-with-platinum-sensitive-relapsed-germline-brca-mutated-advanced-ovarian-cancer-compared-to-51-of-pat\/"},"modified":"2025-05-12T08:58:03","modified_gmt":"2025-05-12T12:58:03","slug":"lynparza-olaparib-phase-3-solo3-trial-demonstrated-a-72-objective-response-rate-in-patients-with-platinum-sensitive-relapsed-germline-brca-mutated-advanced-ovarian-cancer-compared-to-51-of-pat","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-phase-3-solo3-trial-demonstrated-a-72-objective-response-rate-in-patients-with-platinum-sensitive-relapsed-germline-brca-mutated-advanced-ovarian-cancer-compared-to-51-of-pat\/","title":{"rendered":"LYNPARZA\u00ae (olaparib) Phase 3 SOLO3 Trial Demonstrated a 72% Objective Response Rate in Patients with Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer Compared to 51% of Patients Receiving Chemotherapy"},"content":{"rendered":"<p class=\"bwalignc\">       AstraZeneca and Merck\u2019s LYNPARZA Increased the Median Time Without        Disease Progression or Death by 4.2 Months Versus Physician\u2019s Choice of        Chemotherapy Following Two or More Prior Lines of Chemotherapy     <\/p>\n<p class=\"bwalignc\">       AstraZeneca and Merck\u2019s LYNPARZA is the First and Only PARP Inhibitor        to Demonstrate Efficacy Versus Chemotherapy in This Setting     <\/p>\n<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States<br \/>\n      and Canada), today presented full results from the Phase 3 SOLO3 trial<br \/>\n      which evaluated LYNPARZA, compared to chemotherapy, for the treatment of<br \/>\n      platinum-sensitive relapsed patients with germline <i>BRCA1\/2<\/i>-mutated<br \/>\n      (g<i>BRCA<\/i>m) advanced ovarian cancer, who have received two more<br \/>\n      prior lines of chemotherapy. The results were presented at the 55<sup>th<\/sup><br \/>\n      Annual Meeting of the American Society of Clinical Oncology (ASCO) in<br \/>\n      Chicago.\n    <\/p>\n<p>\n      The results from the trial showed a statistically-significant and<br \/>\n      clinically-meaningful improvement in objective response rate (ORR) in<br \/>\n      the LYNPARZA arm compared to the chemotherapy arm (ORR; 72.2% for<br \/>\n      LYNPARZA vs 51.4% for chemotherapy; 95% CI: 1.40 to 4.58; p=0.002).\n    <\/p>\n<p>\n      The key secondary endpoint of progression-free survival (PFS) was also<br \/>\n      significantly increased in the LYNPARZA arm (13.4 months) compared to<br \/>\n      the chemotherapy arm (9.2 months; PFS HR 0.62 [p=0.013]).\n    <\/p>\n<table cellspacing=\"0\" class=\"bwtablemarginb\">\n<tbody>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl bwsinglebottom\" colspan=\"7\">\n<p class=\"bwcellpmargin\">\n            <b>Summary of endpoints<\/b><br \/>\n<sup><br \/>\n<b>[i]<\/b><br \/>\n<\/sup>\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n<p class=\"bwcellpmargin\">\n            LYNPARZA<br \/>(300 mg bd)\n          <\/p>\n<\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0  bwvertalignt bwalignc bwsinglebottom\">\n          Chemotherapy\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwsinglebottom\">\n          <b>ORR (primary endpoint)<\/b>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"4\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwsinglebottom\">\n          Number of patients\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          151\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          72\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwsinglebottom\">\n          Number of patients with response (%)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          109 (72.2%)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          37 (51.4%)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwsinglebottom\">\n          Odds ratio (95% CI)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\" colspan=\"4\">\n          2.53 (1.40, 4.58)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwsinglebottom\">\n          p-value\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\" colspan=\"4\">\n          0.002\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwsinglebottom\">\n          <b>PFS (key secondary endpoint)<\/b><br \/>\n<sup><br \/>\n<b>[ii]<\/b><br \/>\n<\/sup>\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\" colspan=\"4\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwsinglebottom\">\n          Number of patients\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          178\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          88\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwsinglebottom\">\n          Number of patients with event (%)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          110 (61.8%)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          49 (55.7%)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwsinglebottom\">\n          Hazard ratio (95% CI)\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\" colspan=\"4\">\n          0.62 (0.43, 0.91)\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwsinglebottom\">\n          Median in months\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          13.4\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\">\n          9.2\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwsinglebottom\">\n          p-value\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwsinglebottom\">\n          &nbsp;\n        <\/td>\n<td class=\"bwpadl0 bwnowrap bwpadr0 bwvertalignb bwalignc bwsinglebottom\" colspan=\"4\">\n          0.013\n        <\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td>\n          &nbsp;\n        <\/td>\n<td colspan=\"4\">\n        <\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"7\">\n<p class=\"bwcellpmargin\">\n            <sup>i<\/sup>Assessed by blinded independent central review\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"bwpadl0  bwvertalignt bwalignl\" colspan=\"7\">\n<p class=\"bwcellpmargin\">\n            <sup>ii<\/sup>Analysis was done at 64.5% maturity\n          <\/p>\n<\/td>\n<\/tr>\n<tr>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td>\n        <\/td>\n<td colspan=\"4\">\n          &nbsp;\n        <\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<p>\n      Jos\u00e9 Baselga, executive vice president, Oncology R&amp;D, AstraZeneca, said,<br \/>\n      \u201cThis trial shows that LYNPARZA has the potential to provide a<br \/>\n      much-needed improvement and alternative over standard-of-care<br \/>\n      chemotherapy for certain patients with relapsed <i>BRCA<\/i>-mutated<br \/>\n      advanced ovarian cancer. This is the fourth positive Phase 2 or Phase 3<br \/>\n      trial in advanced ovarian cancer for LYNPARZA across multiple lines of<br \/>\n      therapy. We look forward to discussing these results with regulatory<br \/>\n      authorities.\u201d\n    <\/p>\n<p>\n      Dr. Roy Baynes, senior vice president and head of global clinical<br \/>\n      development, chief medical officer, Merck Research Laboratories, said,<br \/>\n      \u201cLYNPARZA is the first and only PARP inhibitor to demonstrate efficacy<br \/>\n      versus chemotherapy in relapsed <i>BRCA<\/i>-mutated advanced ovarian<br \/>\n      cancer following two or more prior lines of chemotherapy. The positive<br \/>\n      SOLO3 results reaffirm AstraZeneca and Merck\u2019s ongoing commitment to<br \/>\n      explore potential treatment options beyond standard-of-care for <i>BRCA-<\/i>mutated<br \/>\n      patients with advanced stage disease.\u201d\n    <\/p>\n<p>\n      The safety and tolerability profile of LYNPARZA in SOLO3 was consistent<br \/>\n      with previous trials. The most common adverse events (AEs) \u2265 20% were<br \/>\n      nausea (64.6%), fatigue\/asthenia (52.2%), anemia (51.1%), vomiting<br \/>\n      (38.2%), diarrhea (28.1%) and abdominal pain (21.3%). The most common \u2265<br \/>\n      Grade 3 AEs were anemia (21.3%), neutropenia (9.6%), fatigue\/asthenia<br \/>\n      (4.5%) and thrombocytopenia (3.9%). AEs led to dose interruption in 48%<br \/>\n      percent of patients on LYNPARZA vs. 42% in the chemotherapy arm, while<br \/>\n      7% of patients discontinued treatment vs. 20% in the chemotherapy arm.\n    <\/p>\n<p>\n      LYNPARZA is currently approved in 64 countries, including those in the<br \/>\n      EU, for the maintenance treatment of platinum-sensitive relapsed ovarian<br \/>\n      cancer regardless of <i>BRCA<\/i> status. It is approved in the U.S. as<br \/>\n      first-line maintenance treatment in <i>BRCA<\/i>m advanced ovarian cancer<br \/>\n      following response to platinum-based chemotherapy. It is also approved<br \/>\n      in 38 countries, including the U.S., countries in the EU and Japan, for<br \/>\n      germline <i>BRCA<\/i>m HER2-negative metastatic breast cancer previously<br \/>\n      treated with chemotherapy; in the EU this includes locally advanced<br \/>\n      breast cancer. Regulatory reviews are underway in other jurisdictions<br \/>\n      for both ovarian cancer and breast cancer.\n    <\/p>\n<p>\n      <b>About SOLO3<\/b><br \/>\n<br \/>SOLO3 is a Phase 3 randomized, open-label,<br \/>\n      controlled, multi-center trial to evaluate the efficacy and safety of<br \/>\n      LYNPARZA tablets following two or more prior lines of chemotherapy. The<br \/>\n      trial randomized 266 patients with a deleterious or suspected<br \/>\n      deleterious <i>BRCA<\/i>1 or <i>BRCA<\/i>2 mutation. Eligible patients<br \/>\n      were randomized (2:1) to receive LYNPARZA 300mg tablets twice daily or<br \/>\n      physician\u2019s choice single-agent chemotherapy (paclitaxel, topotecan,<br \/>\n      pegylated liposomal doxorubicin or gemcitabine). The primary endpoint<br \/>\n      was overall response rate (ORR) by blinded independent central review<br \/>\n      and key secondary endpoints included progression-free survival (PFS),<br \/>\n      time to second disease progression or death and overall survival.\n    <\/p>\n<p>\n      <b>About Ovarian Cancer<\/b><br \/>\n<br \/>Ovarian cancer is a leading cause of<br \/>\n      cancer death in women worldwide, with a five-year survival rate of 19%.<br \/>\n      In 2018, there were over 295,000 new cases diagnosed and around 185,000<br \/>\n      deaths. Over 70% of women with ovarian cancer have advanced disease at<br \/>\n      the time of diagnosis, with up to 80% at risk of recurrence after<br \/>\n      initial treatment. Effective treatments are needed in later lines of<br \/>\n      therapy as patients typically obtain limited benefit after two prior<br \/>\n      lines of chemotherapy.\n    <\/p>\n<p>\n      <b>About <i>BRCA<\/i><br \/>\n<\/b><br \/>\n<br \/>\n<i>BRCA<\/i>1 and <i>BRCA<\/i>2 are human<br \/>\n      genes that produce proteins responsible for repairing damaged DNA and<br \/>\n      play an important role in maintaining the genetic stability of cells.<br \/>\n      When either of these genes is mutated, or altered, such that its protein<br \/>\n      product either is not made or does not function correctly, DNA damage<br \/>\n      may not be repaired properly, and cells become unstable. As a result,<br \/>\n      cells are more likely to develop additional genetic alterations that can<br \/>\n      lead to cancer.\n    <\/p>\n<p>\n      <b>About LYNPARZA<\/b><br \/>\n<sup><br \/>\n<b>\u00ae<\/b><br \/>\n<\/sup><br \/>\n<b> (olaparib)<\/b><br \/>\n<br \/>LYNPARZA<br \/>\n      is a first-in-class PARP inhibitor and the first targeted treatment to<br \/>\n      potentially exploit DNA damage response (DDR) pathway deficiencies, such<br \/>\n      as <i>BRCA <\/i>mutations, to preferentially kill cancer cells.<br \/>\n      Inhibition of PARP with LYNPARZA leads to the trapping of PARP bound to<br \/>\n      DNA single-strand breaks, stalling of replication forks, their collapse<br \/>\n      and the generation of DNA double-strand breaks and cancer cell death.<br \/>\n      LYNPARZA is being tested in a range of tumor types with defects and<br \/>\n      dependencies in the DDR.\n    <\/p>\n<p>\n      LYNPARZA, which is being jointly developed and commercialized by<br \/>\n      AstraZeneca and Merck, has a broad and advanced clinical trial<br \/>\n      development program, and AstraZeneca and Merck are working together to<br \/>\n      understand how it may affect multiple PARP-dependent tumors as a<br \/>\n      monotherapy and in combination across multiple cancer types.\n    <\/p>\n<p>\n      <b>IMPORTANT SAFETY INFORMATION<\/b>\n    <\/p>\n<p>\n      <b>CONTRAINDICATIONS<\/b><br \/>\n<br \/>There are no contraindications for<br \/>\n      LYNPARZA.\n    <\/p>\n<p>\n      <b>WARNINGS AND PRECAUTIONS<\/b><br \/>\n<br \/>\n<b>Myelodysplastic Syndrome\/Acute<br \/>\n      Myeloid Leukemia (MDS\/AML): <\/b>Occurred in &lt;1.5% of patients exposed to<br \/>\n      LYNPARZA monotherapy, and the majority of events had a fatal outcome.<br \/>\n      The duration of therapy in patients who developed secondary MDS\/AML<br \/>\n      varied from &lt;6 months to &gt;2 years. All of these patients had previous<br \/>\n      chemotherapy with platinum agents and\/or other DNA-damaging agents,<br \/>\n      including radiotherapy, and some also had a history of more than one<br \/>\n      primary malignancy or of bone marrow dysplasia.\n    <\/p>\n<p>\n      Do not start LYNPARZA until patients have recovered from hematological<br \/>\n      toxicity caused by previous chemotherapy (\u2264Grade 1). Monitor complete<br \/>\n      blood count for cytopenia at baseline and monthly thereafter for<br \/>\n      clinically significant changes during treatment. For prolonged<br \/>\n      hematological toxicities, interrupt LYNPARZA and monitor blood count<br \/>\n      weekly until recovery.\n    <\/p>\n<p>\n      If the levels have not recovered to Grade 1 or less after 4 weeks, refer<br \/>\n      the patient to a hematologist for further investigations, including bone<br \/>\n      marrow analysis and blood sample for cytogenetics. Discontinue LYNPARZA<br \/>\n      if MDS\/AML is confirmed.\n    <\/p>\n<p>\n      <b>Pneumonitis: <\/b>Occurred in &lt;1% of patients exposed to LYNPARZA, and<br \/>\n      some cases were fatal. If patients present with new or worsening<br \/>\n      respiratory symptoms such as dyspnea, cough, and fever, or a<br \/>\n      radiological abnormality occurs, interrupt LYNPARZA treatment and<br \/>\n      initiate prompt investigation. Discontinue LYNPARZA if pneumonitis is<br \/>\n      confirmed and treat patient appropriately.\n    <\/p>\n<p>\n      <b>Embryo-Fetal Toxicity: <\/b>Based on its mechanism of action and<br \/>\n      findings in animals, LYNPARZA can cause fetal harm. A pregnancy test is<br \/>\n      recommended for females of reproductive potential prior to initiating<br \/>\n      treatment.\n    <\/p>\n<p>\n      <i>Females<\/i><br \/>\n<br \/>Advise females of reproductive potential of the<br \/>\n      potential risk to a fetus and to use effective contraception during<br \/>\n      treatment and for 6 months following the last dose.\n    <\/p>\n<p>\n      <i>Males<\/i><br \/>\n<br \/>Advise male patients with female partners of<br \/>\n      reproductive potential or who are pregnant to use effective<br \/>\n      contraception during treatment and for 3 months following the last dose<br \/>\n      of LYNPARZA and to not donate sperm during this time.\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014First-Line Maintenance <i>BRCA<\/i>m Advanced<br \/>\n      Ovarian Cancer<\/b><br \/>\n<br \/>Most common adverse reactions (Grades 1-4) in<br \/>\n      \u226510% of patients in clinical trials of LYNPARZA in the <b>first-line<br \/>\n      maintenance setting<\/b> for <b>SOLO-1 <\/b>were: nausea (77%), fatigue<br \/>\n      (67%), abdominal pain (45%), vomiting (40%), anemia (38%), diarrhea<br \/>\n      (37%), constipation (28%), upper respiratory tract<br \/>\n      infection\/influenza\/nasopharyngitis\/bronchitis (28%), dysgeusia (26%),<br \/>\n      decreased appetite (20%), dizziness (20%), neutropenia (17%), dyspepsia<br \/>\n      (17%), dyspnea (15%), leukopenia (13%), UTI (13%), thrombocytopenia<br \/>\n      (11%), and stomatitis (11%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>first-line maintenance setting for<br \/>\n      SOLO-1<\/b> were: decrease in hemoglobin (87%), increase in mean<br \/>\n      corpuscular volume (87%), decrease in leukocytes (70%), decrease in<br \/>\n      lymphocytes (67%), decrease in absolute neutrophil count (51%), decrease<br \/>\n      in platelets (35%), and increase in serum creatinine (34%).\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014Maintenance Recurrent Ovarian Cancer<\/b><br \/>\n<br \/>Most<br \/>\n      common adverse reactions (Grades 1-4) in \u226520% of patients in clinical<br \/>\n      trials of LYNPARZA in the <b>maintenance setting <\/b>for <b>SOLO-2<\/b><br \/>\n      were: nausea (76%), fatigue (including asthenia) (66%), anemia (44%),<br \/>\n      vomiting (37%), nasopharyngitis\/upper respiratory tract infection<br \/>\n      (URI)\/influenza (36%), diarrhea (33%), arthralgia\/myalgia (30%),<br \/>\n      dysgeusia (27%), headache (26%), decreased appetite (22%), and<br \/>\n      stomatitis (20%).\n    <\/p>\n<p>\n      <b>Study 19: <\/b>nausea (71%), fatigue (including asthenia) (63%),<br \/>\n      vomiting (35%), diarrhea (28%), anemia (23%), respiratory tract<br \/>\n      infection (22%), constipation (22%), headache (21%), decreased appetite<br \/>\n      (21%), and dyspepsia (20%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA in the <b>maintenance setting (SOLO-2\/Study<br \/>\n      19<\/b>) were: increase in mean corpuscular volume (89%\/82%), decrease in<br \/>\n      hemoglobin (83%\/82%), decrease in leukocytes (69%\/58%), decrease in<br \/>\n      lymphocytes (67%\/52%), decrease in absolute neutrophil count (51%\/47%),<br \/>\n      increase in serum creatinine (44%\/45%), and decrease in platelets<br \/>\n      (42%\/36%).\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014Advanced g<i>BRCA<\/i>m ovarian cancer<\/b><br \/>\n<br \/>Most<br \/>\n      common adverse reactions (Grades 1-4) in \u226520% of patients in clinical<br \/>\n      trials of LYNPARZA for <b>advanced g<i>BRCA<\/i>m ovarian cancer after 3<br \/>\n      or more lines of chemotherapy <\/b>(pooled from 6 studies) were:<br \/>\n      fatigue\/asthenia (66%), nausea (64%), vomiting (43%), anemia (34%),<br \/>\n      diarrhea (31%), nasopharyngitis\/upper respiratory tract infection (URI)<br \/>\n      (26%), dyspepsia (25%), myalgia (22%), decreased appetite (22%), and<br \/>\n      arthralgia\/musculoskeletal pain (21%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in<br \/>\n      clinical trials of LYNPARZA for <b>advanced g<i>BRCA<\/i>m ovarian cancer <\/b>(pooled<br \/>\n      from 6 studies) were: decrease in hemoglobin (90%), mean corpuscular<br \/>\n      volume elevation (57%), decrease in lymphocytes (56%), increase in serum<br \/>\n      creatinine (30%), decrease in platelets (30%), and decrease in absolute<br \/>\n      neutrophil count (25%).\n    <\/p>\n<p>\n      <b>ADVERSE REACTIONS\u2014g<i>BRCA<\/i>m, HER2-negative metastatic breast<br \/>\n      cancer<\/b><br \/>\n<br \/>Most common adverse reactions (Grades 1-4) in \u226520% of<br \/>\n      patients in <b>OlympiAD<\/b> were: nausea (58%), anemia (40%), fatigue<br \/>\n      (including asthenia) (37%), vomiting (30%), neutropenia (27%),<br \/>\n      respiratory tract infection (27%), leukopenia (25%), diarrhea (21%), and<br \/>\n      headache (20%).\n    <\/p>\n<p>\n      Most common laboratory abnormalities (Grades 1-4) in \u226525% of patients in <b>OlympiAD<br \/>\n      <\/b>were: decrease in hemoglobin (82%), decrease in lymphocytes (73%),<br \/>\n      decrease in leukocytes (71%), increase in mean corpuscular volume (71%),<br \/>\n      decrease in absolute neutrophil count (46%), and decrease in platelets<br \/>\n      (33%).\n    <\/p>\n<p>\n      <b>DRUG INTERACTIONS<\/b>\n    <\/p>\n<p>\n      <b>Anticancer Agents: <\/b>Clinical studies of LYNPARZA in combination<br \/>\n      with other myelosuppressive anticancer agents, including DNA-damaging<br \/>\n      agents, indicate a potentiation and prolongation of myelosuppressive<br \/>\n      toxicity.\n    <\/p>\n<p>\n      <b>CYP3A Inhibitors: <\/b>Avoid concomitant use of strong or moderate<br \/>\n      CYP3A inhibitors. If a strong or moderate CYP3A inhibitor must be<br \/>\n      co-administered, reduce the dose of LYNPARZA. Advise patients to avoid<br \/>\n      grapefruit, grapefruit juice, Seville oranges, and Seville orange juice<br \/>\n      during LYNPARZA treatment.\n    <\/p>\n<p>\n      <b>CYP3A Inducers: <\/b>Avoid concomitant use of strong or moderate CYP3A<br \/>\n      inducers when using LYNPARZA. If a moderate inducer cannot be avoided,<br \/>\n      there is a potential for decreased efficacy of LYNPARZA.\n    <\/p>\n<p>\n      <b>USE IN SPECIFIC POPULATIONS<\/b>\n    <\/p>\n<p>\n      <b>Lactation: <\/b>No data are available regarding the presence of<br \/>\n      olaparib in human milk, its effects on the breastfed infant or on milk<br \/>\n      production. Because of the potential for serious adverse reactions in<br \/>\n      the breastfed infant, advise a lactating woman not to breastfeed during<br \/>\n      treatment with LYNPARZA and for 1 month after receiving the final dose.\n    <\/p>\n<p>\n      <b>Pediatric Use: <\/b>The safety and efficacy of LYNPARZA have not been<br \/>\n      established in pediatric patients.\n    <\/p>\n<p>\n      <b>Hepatic Impairment: <\/b>No adjustment to the starting dose is<br \/>\n      required in patients with mild or moderate hepatic impairment<br \/>\n      (Child-Pugh classification A and B). There are no data in patients with<br \/>\n      severe hepatic impairment (Child-Pugh classification C).\n    <\/p>\n<p>\n      <b>Renal Impairment: <\/b>No adjustment to the starting dose is necessary<br \/>\n      in patients with mild renal impairment (CLcr=51-80 mL\/min) but patients<br \/>\n      should be monitored closely for toxicity. In patients with moderate<br \/>\n      renal impairment (CLcr=31-50 mL\/min), reduce the dose to 200 mg twice<br \/>\n      daily. There are no data in patients with severe renal impairment or<br \/>\n      end-stage renal disease (CLcr \u226430 mL\/min).\n    <\/p>\n<p>\n      <b>INDICATIONS<\/b>\n    <\/p>\n<p>\n      LYNPARZA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated:\n    <\/p>\n<p>\n      <b>First-Line Maintenance <i>BRCA<\/i>m Advanced Ovarian Cancer<\/b><br \/>\n<br \/>For<br \/>\n      the maintenance treatment of adult patients with deleterious or<br \/>\n      suspected deleterious germline or somatic <i>BRCA<\/i>-mutated (g<i>BRCA<\/i>m<i><br \/>\n      <\/i>or s<i>BRCA<\/i>m) advanced epithelial ovarian, fallopian tube or<br \/>\n      primary peritoneal cancer who are in complete or partial response to<br \/>\n      first-line platinum-based chemotherapy. Select patients with g<i>BRCA<\/i>m<br \/>\n      advanced epithelial ovarian, fallopian tube or primary peritoneal cancer<br \/>\n      for therapy based on an FDA-approved companion diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      <b>Maintenance Recurrent Ovarian Cancer<\/b><br \/>\n<br \/>For the maintenance<br \/>\n      treatment of adult patients with recurrent epithelial ovarian, fallopian<br \/>\n      tube, or primary peritoneal cancer, who are in complete or partial<br \/>\n      response to platinum-based chemotherapy.\n    <\/p>\n<p>\n      <b>Advanced g<i>BRCA<\/i>m ovarian cancer<\/b><br \/>\n<br \/>For the treatment of<br \/>\n      adult patients with deleterious or suspected deleterious germline <i>BRCA-<\/i>mutated<br \/>\n      (g<i>BRCA<\/i>m) advanced ovarian cancer who have been treated with 3 or<br \/>\n      more prior lines of chemotherapy. Select patients for therapy based on<br \/>\n      an FDA-approved companion diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      <b>g<i>BRCA<\/i>m, HER2-negative metastatic breast cancer<\/b><br \/>\n<br \/>In<br \/>\n      patients with deleterious or suspected deleterious g<i>BRCA<\/i>m<i>, <\/i>human<br \/>\n      epidermal growth factor receptor 2 (HER2)-negative metastatic breast<br \/>\n      cancer who have been treated with chemotherapy in the neoadjuvant,<br \/>\n      adjuvant or metastatic setting. Patients with hormone receptor<br \/>\n      (HR)-positive breast cancer should have been treated with a prior<br \/>\n      endocrine therapy or be considered inappropriate for endocrine therapy.<br \/>\n      Select patients for therapy based on an FDA-approved companion<br \/>\n      diagnostic for LYNPARZA.\n    <\/p>\n<p>\n      <b>Please <\/b><br \/>\n<a href=\"https:\/\/www.azpicentral.com\/lynparza_tb\/lynparza_tb.pdf\" rel=\"nofollow\"><br \/>\n<b>click<br \/>\n      here for complete Prescribing Information, including Patient Information<br \/>\n      (Medication Guide)<\/b><br \/>\n<\/a><br \/>\n<b>.<\/b>\n    <\/p>\n<p>\n      <b>About the AstraZeneca and Merck Strategic Oncology Collaboration<\/b><br \/>\n<br \/>In<br \/>\n      July 2017, AstraZeneca and Merck, known as MSD outside the United States<br \/>\n      and Canada, announced a global strategic oncology collaboration to<br \/>\n      co-develop and co-commercialize LYNPARZA, the world\u2019s first PARP<br \/>\n      inhibitor, and potential new medicine selumetinib, a MEK inhibitor, for<br \/>\n      multiple cancer types. Working together, the companies will develop<br \/>\n      LYNPARZA and selumetinib in combination with other potential new<br \/>\n      medicines and as monotherapies. Independently, the companies will<br \/>\n      develop LYNPARZA and selumetinib in combination with their respective<br \/>\n      PD-L1 and PD-1 medicines.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b><br \/>\n<br \/>Our goal is to translate<br \/>\n      breakthrough science into innovative oncology medicines to help people<br \/>\n      with cancer worldwide. At Merck, the potential to bring new hope to<br \/>\n      people with cancer drives our purpose and supporting accessibility to<br \/>\n      our cancer medicines is our commitment. As part of our focus on cancer,<br \/>\n      Merck is committed to exploring the potential of immuno-oncology with<br \/>\n      one of the largest development programs in the industry across more than<br \/>\n      30 tumor types. We also continue to strengthen our portfolio through<br \/>\n      strategic acquisitions and are prioritizing the development of several<br \/>\n      promising oncology candidates with the potential to improve the<br \/>\n      treatment of advanced cancers. For more information about our oncology<br \/>\n      clinical trials, visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/clinicaltrials\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b><br \/>\n<br \/>For more than a century, Merck, a leading global<br \/>\n      biopharmaceutical company known as MSD outside of the United States and<br \/>\n      Canada, has been inventing for life, bringing forward medicines and<br \/>\n      vaccines for many of the world\u2019s most challenging diseases. Through our<br \/>\n      prescription medicines, vaccines, biologic therapies and animal health<br \/>\n      products, we work with customers and operate in more than 140 countries<br \/>\n      to deliver innovative health solutions. We also demonstrate our<br \/>\n      commitment to increasing access to health care through far-reaching<br \/>\n      policies, programs and partnerships. Today, Merck continues to be at the<br \/>\n      forefront of research to advance the prevention and treatment of<br \/>\n      diseases that threaten people and communities around the world &#8211;<br \/>\n      including cancer, cardio-metabolic diseases, emerging animal diseases,<br \/>\n      Alzheimer\u2019s disease and infectious diseases including HIV and Ebola. For<br \/>\n      more information, visit&nbsp;<a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\/index.html\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and&nbsp;connect with us on&nbsp;<a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>,&nbsp;<a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>,&nbsp;<a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"http:\/\/www.youtube.com\/Merck\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and&nbsp;<a href=\"https:\/\/www.linkedin.com\/company\/merck\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b><br \/>\n<br \/>This<br \/>\n      news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the \u201ccompany\u201d)<br \/>\n      includes \u201cforward-looking statements\u201d within the meaning of the safe<br \/>\n      harbor provisions of the U.S. Private Securities Litigation Reform Act<br \/>\n      of 1995. These statements are based upon the current beliefs and<br \/>\n      expectations of the company\u2019s management and are subject to significant<br \/>\n      risks and uncertainties. There can be no guarantees with respect to<br \/>\n      pipeline products that the products will receive the necessary<br \/>\n      regulatory approvals or that they will prove to be commercially<br \/>\n      successful. If underlying assumptions prove inaccurate or risks or<br \/>\n      uncertainties materialize, actual results may differ materially from<br \/>\n      those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2018 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" style=\"width:0;height:0\"><br \/>\n<span class=\"bwct31415\"><br \/>\n<\/span><\/p>\n<p>       Media:<br \/>Pamela Eisele<br \/>(267) 305-3558     <\/p>\n<p>       Michael Close<br \/>(267) 305-1211     <\/p>\n<p>       Investors:<br \/>Teri Loxam<br \/>(908) 740-1986     <\/p>\n<p>       Michael DeCarbo<br \/>(908) 740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada), today presented full results from the Phase 3 SOLO3 trial which evaluated LYNPARZA, compared to chemotherapy, for the treatment of platinum-sensitive relapsed patients with germline BRCA1\/2 -mutated (g BRCA m) advanced ovarian cancer, who have received two more prior lines of chemotherapy. The results were presented at the 55 th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The results from the trial showed a statistically-significant and clinically-meaningful improvement in objective response rate (ORR) in the LYNPARZA arm compared to the chemotherapy arm (ORR; 72.2% for LYNPARZA vs 51.4% for chemotherapy; 95% CI: 1.40 to 4.58; p=0.002). The key secondary endpoint of progression-free survival (PFS) was also significantly increased in the LYNPARZA arm (13.4 months) compared to the chemotherapy arm (9.2 months; PFS HR 0.62 [p=0.013]). Summary of endpoints [i] &nbsp;<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,289,56],"class_list":["post-746023","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>LYNPARZA\u00ae (olaparib) Phase 3 SOLO3 Trial Demonstrated a 72% Objective Response Rate in Patients with Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer Compared to 51% of Patients Receiving Chemotherapy - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-phase-3-solo3-trial-demonstrated-a-72-objective-response-rate-in-patients-with-platinum-sensitive-relapsed-germline-brca-mutated-advanced-ovarian-cancer-compared-to-51-of-pat\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"LYNPARZA\u00ae (olaparib) Phase 3 SOLO3 Trial Demonstrated a 72% Objective Response Rate in Patients with Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer Compared to 51% of Patients Receiving Chemotherapy - Merck.com\" \/>\n<meta property=\"og:description\" content=\"AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada), today presented full results from the Phase 3 SOLO3 trial which evaluated LYNPARZA, compared to chemotherapy, for the treatment of platinum-sensitive relapsed patients with germline BRCA1\/2 -mutated (g BRCA m) advanced ovarian cancer, who have received two more prior lines of chemotherapy. The results were presented at the 55 th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The results from the trial showed a statistically-significant and clinically-meaningful improvement in objective response rate (ORR) in the LYNPARZA arm compared to the chemotherapy arm (ORR; 72.2% for LYNPARZA vs 51.4% for chemotherapy; 95% CI: 1.40 to 4.58; p=0.002). The key secondary endpoint of progression-free survival (PFS) was also significantly increased in the LYNPARZA arm (13.4 months) compared to the chemotherapy arm (9.2 months; PFS HR 0.62 [p=0.013]). Summary of endpoints [i] &nbsp;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-phase-3-solo3-trial-demonstrated-a-72-objective-response-rate-in-patients-with-platinum-sensitive-relapsed-germline-brca-mutated-advanced-ovarian-cancer-compared-to-51-of-pat\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-12T12:58:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.businesswire.com\/images\/spacer.gif\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"14 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-phase-3-solo3-trial-demonstrated-a-72-objective-response-rate-in-patients-with-platinum-sensitive-relapsed-germline-brca-mutated-advanced-ovarian-cancer-compared-to-51-of-pat\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-phase-3-solo3-trial-demonstrated-a-72-objective-response-rate-in-patients-with-platinum-sensitive-relapsed-germline-brca-mutated-advanced-ovarian-cancer-compared-to-51-of-pat\\\/\",\"name\":\"LYNPARZA\u00ae (olaparib) Phase 3 SOLO3 Trial Demonstrated a 72% Objective Response Rate in Patients with Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer Compared to 51% of Patients Receiving Chemotherapy - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-phase-3-solo3-trial-demonstrated-a-72-objective-response-rate-in-patients-with-platinum-sensitive-relapsed-germline-brca-mutated-advanced-ovarian-cancer-compared-to-51-of-pat\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-phase-3-solo3-trial-demonstrated-a-72-objective-response-rate-in-patients-with-platinum-sensitive-relapsed-germline-brca-mutated-advanced-ovarian-cancer-compared-to-51-of-pat\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"datePublished\":\"2019-06-03T15:15:00+00:00\",\"dateModified\":\"2025-05-12T12:58:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-phase-3-solo3-trial-demonstrated-a-72-objective-response-rate-in-patients-with-platinum-sensitive-relapsed-germline-brca-mutated-advanced-ovarian-cancer-compared-to-51-of-pat\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-phase-3-solo3-trial-demonstrated-a-72-objective-response-rate-in-patients-with-platinum-sensitive-relapsed-germline-brca-mutated-advanced-ovarian-cancer-compared-to-51-of-pat\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-phase-3-solo3-trial-demonstrated-a-72-objective-response-rate-in-patients-with-platinum-sensitive-relapsed-germline-brca-mutated-advanced-ovarian-cancer-compared-to-51-of-pat\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\",\"contentUrl\":\"https:\\\/\\\/www.businesswire.com\\\/images\\\/spacer.gif\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/lynparza-olaparib-phase-3-solo3-trial-demonstrated-a-72-objective-response-rate-in-patients-with-platinum-sensitive-relapsed-germline-brca-mutated-advanced-ovarian-cancer-compared-to-51-of-pat\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"LYNPARZA\u00ae (olaparib) Phase 3 SOLO3 Trial Demonstrated a 72% Objective Response Rate in Patients with Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer Compared to 51% of Patients Receiving Chemotherapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"LYNPARZA\u00ae (olaparib) Phase 3 SOLO3 Trial Demonstrated a 72% Objective Response Rate in Patients with Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer Compared to 51% of Patients Receiving Chemotherapy - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-phase-3-solo3-trial-demonstrated-a-72-objective-response-rate-in-patients-with-platinum-sensitive-relapsed-germline-brca-mutated-advanced-ovarian-cancer-compared-to-51-of-pat\/","og_locale":"en_US","og_type":"article","og_title":"LYNPARZA\u00ae (olaparib) Phase 3 SOLO3 Trial Demonstrated a 72% Objective Response Rate in Patients with Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer Compared to 51% of Patients Receiving Chemotherapy - Merck.com","og_description":"AstraZeneca and Merck (NYSE:MRK), known as MSD outside the United States and Canada), today presented full results from the Phase 3 SOLO3 trial which evaluated LYNPARZA, compared to chemotherapy, for the treatment of platinum-sensitive relapsed patients with germline BRCA1\/2 -mutated (g BRCA m) advanced ovarian cancer, who have received two more prior lines of chemotherapy. The results were presented at the 55 th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. The results from the trial showed a statistically-significant and clinically-meaningful improvement in objective response rate (ORR) in the LYNPARZA arm compared to the chemotherapy arm (ORR; 72.2% for LYNPARZA vs 51.4% for chemotherapy; 95% CI: 1.40 to 4.58; p=0.002). The key secondary endpoint of progression-free survival (PFS) was also significantly increased in the LYNPARZA arm (13.4 months) compared to the chemotherapy arm (9.2 months; PFS HR 0.62 [p=0.013]). Summary of endpoints [i] &nbsp;","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-phase-3-solo3-trial-demonstrated-a-72-objective-response-rate-in-patients-with-platinum-sensitive-relapsed-germline-brca-mutated-advanced-ovarian-cancer-compared-to-51-of-pat\/","og_site_name":"Merck.com","article_modified_time":"2025-05-12T12:58:03+00:00","og_image":[{"url":"https:\/\/www.businesswire.com\/images\/spacer.gif","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"14 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-phase-3-solo3-trial-demonstrated-a-72-objective-response-rate-in-patients-with-platinum-sensitive-relapsed-germline-brca-mutated-advanced-ovarian-cancer-compared-to-51-of-pat\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-phase-3-solo3-trial-demonstrated-a-72-objective-response-rate-in-patients-with-platinum-sensitive-relapsed-germline-brca-mutated-advanced-ovarian-cancer-compared-to-51-of-pat\/","name":"LYNPARZA\u00ae (olaparib) Phase 3 SOLO3 Trial Demonstrated a 72% Objective Response Rate in Patients with Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer Compared to 51% of Patients Receiving Chemotherapy - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-phase-3-solo3-trial-demonstrated-a-72-objective-response-rate-in-patients-with-platinum-sensitive-relapsed-germline-brca-mutated-advanced-ovarian-cancer-compared-to-51-of-pat\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-phase-3-solo3-trial-demonstrated-a-72-objective-response-rate-in-patients-with-platinum-sensitive-relapsed-germline-brca-mutated-advanced-ovarian-cancer-compared-to-51-of-pat\/#primaryimage"},"thumbnailUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif","datePublished":"2019-06-03T15:15:00+00:00","dateModified":"2025-05-12T12:58:03+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-phase-3-solo3-trial-demonstrated-a-72-objective-response-rate-in-patients-with-platinum-sensitive-relapsed-germline-brca-mutated-advanced-ovarian-cancer-compared-to-51-of-pat\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-phase-3-solo3-trial-demonstrated-a-72-objective-response-rate-in-patients-with-platinum-sensitive-relapsed-germline-brca-mutated-advanced-ovarian-cancer-compared-to-51-of-pat\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-phase-3-solo3-trial-demonstrated-a-72-objective-response-rate-in-patients-with-platinum-sensitive-relapsed-germline-brca-mutated-advanced-ovarian-cancer-compared-to-51-of-pat\/#primaryimage","url":"https:\/\/www.businesswire.com\/images\/spacer.gif","contentUrl":"https:\/\/www.businesswire.com\/images\/spacer.gif"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/lynparza-olaparib-phase-3-solo3-trial-demonstrated-a-72-objective-response-rate-in-patients-with-platinum-sensitive-relapsed-germline-brca-mutated-advanced-ovarian-cancer-compared-to-51-of-pat\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"LYNPARZA\u00ae (olaparib) Phase 3 SOLO3 Trial Demonstrated a 72% Objective Response Rate in Patients with Platinum-Sensitive Relapsed Germline BRCA-mutated Advanced Ovarian Cancer Compared to 51% of Patients Receiving Chemotherapy"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"6340b4d5-1889-45b7-809f-0f55647d082f","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/LYNPARZA-olaparib-Phase-3-SOLO3-Trial-Demonstrated-a-72-Objective-Response-Rate-in-Patients-with-Platinum-Sensitive-Relapsed-Germline-FMO86.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746023","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/746023\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=746023"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=746023"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}